The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000669392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
22/04/2026
Date registered
Help: Date registered
4/06/2026
Date last updated
Help: Date last updated
4/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
4/06/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
A Study Testing the Bioavailability of the Oral Drug FT2109 as a Formulated Capsule in Healthy Participants.
Scientific title
A Randomized, Open-Label Study to Evaluate the Relative Bioavailability, Safety, Tolerability, and Pharmacokinetics of FT2109 Formulated Capsule Compared with FT2109 Active Pharmaceutical Ingredient Capsule Following Single Oral Doses in Healthy Participants
Additional trial identifiers [1] 316842 0
FT2109-1001
Universal Trial Number (UTN)
Trial acronym
Related trial records
This study is related to ACTRN12625001024437, which represents Part A and Part B of the overall study, and ACTRN12625001035415 which represents Part C of the overall study.

Health condition
Health condition(s) studied:
Inflammatory diseases 341210 0
Condition category
Condition code
Inflammatory and Immune System 337298 337298 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants will receive a single dose of each formulation in a cross-over design, with a 10-day washout period between administrations (Day 1 and Day 12)

FT2109 Active Pharmaceutical Ingredient (API) capsules will be administered at a dose of 50 mg. Participants will receive a single 50 mg dose of FT2109 API capsule on Day 1 and a single 50 mg dose of FT2109 formulated capsule on Day 12.

Mode of administration: Oral capsule.

Strategies for monitoring adherence to the intervention:
-Drug capsule accountability will be recorded at dispensing and following dosing.
-Doses will be administered under supervision by trained site staff, including hand and mouth checks following administration, documented in participant source records.
-Blood samples will be collected for pharmacokinetic analysis.
Intervention code [1] 333537 0
Treatment: Drugs
Description of the comparator or control
FT2109 API capsule will be administered as the reference (comparator) formulation at a dose of 50 mg. Participants will receive a single oral dose of the FT2109 API capsule on Day 1 in a cross-over design, followed by a 10-day washout period prior to administration of the test formulation on Day 12.

Mode of administration: Oral capsule.

Strategies for monitoring adherence to the comparator:
-Drug capsule accountability will be recorded at dispensing and following dosing.
-Doses will be administered under supervision by trained site staff, including hand and mouth checks following administration, documented in participant source records.
-Blood samples will be collected for pharmacokinetic analysis
Control group
Active

Outcomes
Primary outcome [1] 344810 0
To assess the relative bioavailability of FT2109 formulated capsule compared to FT2109 API in a capsule following single doses in healthy participants.
Timepoint [1] 344810 0
Blood plasma samples will be assessed at the following timepoints: Dosing Period 1: Day 1, pre-dose,0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 hrs post-dose, Day 2, 24 hrs post-dose, Day 3 48 hrs post-dose, Day 5 post-dose. Dosing Period 2: Day 12, pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 hrs post-dose, Day 13, 24hrs post-dose, Day 14 48 hrs post-dose, Day 16 post-dose, and Day 19 - End of Study/Early Termination (EOS/ET).
Secondary outcome [1] 459418 0
Safety and tolerability will be assessed as a composite secondary outcome. The composite outcome includes evaluation of safety and tolerability of FT2109 formulated capsule following a single dose in healthy participants, based on adverse events, safety laboratory parameters, vital signs, and electrocardiograms.
Timepoint [1] 459418 0
-Adverse event monitoring from screening until end of study (EOS). Any adverse events may be followed beyond this period as clinically indicated. -Vital signs assessed at each visit from screening to EOS (screening, Day 1 pre-dose and at 2, 4, and 8 hours post-dose 1, Day 2 post-dose 1, Day 3 post-dose 1, Day 5 post-dose 1, Day 12 pre-dose and at 2, 4, and 8 hours post-dose 2, Day 13 post-dose 2, Day 14 post-dose 2, Day 16 post-dose 2, Day 19/EOS post-dose 2). -Physical examination conducted at screening and EOS. -Electrocardiograms (ECGs) performed at each visit from screening to EOS (screening, Day 1 pre-dose and at 2, 4, and 8 hours post-dose 1, Day 2 post-dose 1, Day 3 post-dose 1, Day 5 post-dose 1, Day 12 pre-dose and at 2, 4, and 8 hours post-dose 2, Day 13 post-dose 2, Day 14 post-dose 2, Day 16 post-dose 2, Day 19/EOS post-dose 2). -Concomitant medications recorded at each visit from Day 1 to Day 19/EOS. -Clinical safety laboratory tests performed at Screening, Day -1, Day 2 post-dose 1, Day 5 post-dose 1, Day 11 pre-dose 2, Day 13 post-dose 2, Day 16 post-dose 2, and Day 19/EOS post-dose 2.

Eligibility
Key inclusion criteria
Volunteers will be included in the study only if they satisfy all of the following criteria:
1. Must have given written informed consent before any study-related activities are performed and must be able to understand the full nature and purpose of the study, including possible risks and adverse effects.
2. Adult males and females, 18 to 55 years of age (inclusive) at screening.
3. Body mass index (BMI) greater than or equal to 18.0 and less than or equal to 32.0 kg/m², and body weight greater than or equal to 50.0 kg (males) and greater than or equal to 45 kg (females) at screening.
4. Medically healthy (in the opinion of the PI or delegate), as determined by pre-study medical history, and without clinically significant abnormalities including the following:
a. Physical examination without any clinically relevant findings.
b. Systolic blood pressure in the range of 90 to 150 mmHg and diastolic blood pressure in the range of 40 to 90 mmHg after resting for 5 minutes in a supine or semi-supine position.
c. Pulse rate in the range of 40 to 100 beats per minute (bpm) after 5 minutes resting in a supine or semi-supine position.
d. Body temperature (tympanic), between 35.5°C and 37.7°C.
e. Electrocardiogram without clinically significant abnormalities including QTcF less than 450 msec for males and less than 470 msec for females.
f. No clinically significant findings in clinical chemistry, hematology, coagulation, and urinalysis tests.
5. Female volunteers:
a. Must be of non-childbearing potential i.e., surgically sterilized (hysterectomy, bilateral salpingectomy, bilateral oophorectomy) at least 6 weeks before the screening visit or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and a follicle-stimulating hormone [FSH] level consistent with postmenopausal status, per local laboratory guidelines), or
b. If of childbearing potential, must:
i. Have a negative pregnancy test at the screening visit and on admission to the study site on Day -1.
ii. Agree not to attempt to become pregnant or donate ova from signing the informed consent form until at least 30 days after the last dose of study drug.
iii. Agree to use adequate contraception (defined as use of a condom by the male partner combined with use of a highly effective method of contraception) from signing the informed consent form until at least 30 days after the last dose of study drug, if not exclusively in a same-sex relationship or abstinent as a committed lifestyle.
6. Male volunteers:
a. Must agree not to donate sperm from signing the informed consent form until at least 90 days after the last dose of study drug.
b. If engaging in sexual intercourse with a female partner who could become pregnant, must agree to use adequate contraception (defined as use of a condom combined with use of a highly effective method of contraception) from signing the informed consent form until at least 90 days after the last dose of study drug.
c. If engaging in sexual intercourse with a female partner who is not of childbearing potential, must agree to use a condom from signing the informed consent form until at least 90 days after the last dose of study drug.
7. Have suitable venous access for blood sampling.
8. Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
Volunteers will be excluded from the study if they meet any of the following criteria:
1. Known hypersensitivity to the study drug or any of the study drug ingredients.
2. History of anaphylaxis or other significant allergy which, in the opinion of the Principal Investigator (or delegate), would interfere with the volunteer’s ability to participate in the study.
3. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, psychiatric, or neurological disease/disorder, including any acute illness within the past 3 months, determined by the Principal Investigator (or delegate) to be clinically relevant.
4. Previous exposure to any tumour necrosis factor (TNF) inhibitors or antagonists within 3 months prior to study drug administration.
5. History of surgery or hospitalisation within 3 months prior to screening, or surgery planned during the study.
6. Any history of malignant disease in the last 10 years (excluding surgically resected skin squamous cell or basal cell carcinoma).
7. Presence of clinically relevant immunosuppression, including immunodeficiency conditions such as common variable hypogammaglobulinemia.
8. History of risk factors for torsade de pointes (including family history of long QT syndrome or sudden cardiac death) or known arrhythmia.
9. Presence or sequelae of gastrointestinal, liver (including Gilbert’s syndrome), kidney, or other conditions known to interfere with absorption, distribution, metabolism, or excretion of drugs.
10. Liver function test results elevated more than 1.5 times the upper limit of normal for gamma glutamyl transferase, bilirubin (total, conjugated and unconjugated), alkaline phosphatase, aspartate aminotransferase, or alanine aminotransferase.
11. Estimated glomerular filtration rate less than 80 mL/min/1.73 m² using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (2021).
12. History of or positive test results for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus antibodies at the screening visit.
13. Positive drugs of abuse test, carbon monoxide breath test, or alcohol breath test at the screening visit and/or on admission to the study site on Day -1.
14. Regular consumption of more than 10 standard alcoholic drinks per week and/or more than 4 standard alcoholic drinks on any one day (where 1 standard drink is 10 g of pure alcohol and is equivalent to 285 mL beer [4.9% alcohol/volume], 100 mL wine [12% alcohol/volume], or 30 mL spirit [40% alcohol/volume]) and unwillingness to abstain from alcohol for at least 24 hours prior to Day -1 and while confined to the study site.
15. Any use of tobacco-containing products or nicotine-containing products within 3 months prior to Day -1, and/or unwillingness to abstain from smoking or nicotine use for 3 months prior to check-in on Day -1 and throughout the confinement period at the study site and until end of study (non-smokers preferred).
16. Females who are breastfeeding or planning to breastfeed.
17. Unable to swallow oral medication.
18. Use of any prescription or over-the-counter medication (including herbal products, diet aids, vitamins, and hormone supplements) within 7 days (or 14 days if the drug is a potential cytochrome P450 3A4/5 enzyme inducer or inhibitor) or 5 half-lives of the medication (whichever is longer) prior to first dose of study drug, except for ibuprofen (up to 1200 mg per day) or paracetamol (up to 2 g per day) for no more than 3 consecutive days.
19. Consumption of poppy seeds or products containing poppy seeds within 2 days prior to screening and 2 days prior to check-in on Day -1; consumption of Seville orange, grapefruit, or their juices within 7 days prior to study drug administration until end of study. Excessive caffeine or xanthene intake (more than 3 cups per day of coffee, tea, chocolate, or caffeine-containing beverages) with abstinence required from 24 hours prior to study drug administration and during confinement.
20. Current infection requiring systemically absorbed antibiotic, antifungal, antiparasitic, or antiviral medication within 10 days prior to first dose of study drug.
21. History of opportunistic infections (such as herpes zoster, mycoplasma, Pneumocystis jirovecii, histoplasma, Aspergillus, or Mycobacterium) within 6 months prior to screening.
22. Known recurrent or chronic infectious disease history, including but not limited to chronic kidney infection, chronic chest infection (such as bronchiectasis), nasosinusitis, recurrent urinary tract infection, or open, draining, or infected skin wounds.
23. Tuberculosis history or suspected clinically active tuberculosis (including pulmonary, lymphoid, or pleural tuberculosis), or a positive tuberculosis spot test.
24. Use of live (attenuated) vaccines within 3 months and/or non-live vaccines within 1 month prior to Day -1, or plans to receive such vaccines during the trial or within 2 weeks after end of study.
25. Donation of blood or plasma within 30 days prior to first dose of study drug, loss of more than 500 mL of whole blood within 30 days prior to first dose, or receipt of a blood transfusion within 1 year prior to first dose.
26. Receipt of an investigational drug or use of an investigational device in another clinical study within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to screening.
27. Any other condition or prior therapy that, in the opinion of the Principal Investigator (or delegate), would make the volunteer unsuitable for this study, including inability to cooperate fully with study requirements or likelihood of noncompliance with study procedures.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Bio-availability
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 321439 0
Commercial sector/Industry
Name [1] 321439 0
Forward Therapeutics Australia Pty Ltd
Country [1] 321439 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Forward Therapeutics Australia Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 324182 0
Commercial sector/Industry
Name [1] 324182 0
Avance Clinical Pty Ltd
Address [1] 324182 0
Country [1] 324182 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319976 0
Bellberry Human Research Ethics Committee H
Ethics committee address [1] 319976 0
Ethics committee country [1] 319976 0
Australia
Date submitted for ethics approval [1] 319976 0
18/02/2026
Approval date [1] 319976 0
05/03/2026
Ethics approval number [1] 319976 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149014 0
Dr Christopher Argent
Address 149014 0
Scientia Clinical Research, The Bright Building, Level 5, Corner High & Avoca Streets, Randwick NSW 2031,Australia
Country 149014 0
Australia
Phone 149014 0
+61 433182115
Fax 149014 0
Email 149014 0
Contact person for public queries
Name 149015 0
Dr Christopher Argent
Address 149015 0
Scientia Clinical Research, The Bright Building, Level 5, Corner High & Avoca Streets, Randwick NSW 2031,Australia
Country 149015 0
Australia
Phone 149015 0
+61 433182115
Fax 149015 0
Email 149015 0
Contact person for scientific queries
Name 149016 0
Dr Christopher Argent
Address 149016 0
Scientia Clinical Research, The Bright Building, Level 5, Corner High & Avoca Streets, Randwick NSW 2031,Australia
Country 149016 0
Australia
Phone 149016 0
+61 433182115
Fax 149016 0
Email 149016 0

Data sharing statement
Will the study consider sharing individual participant data?
No



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.